Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,648

Document Document Title
WO/2024/076951A2
The application provides compounds of Formula (I) as further defined herein, pharmaceutical compositions comprising said compounds, and methods of using said compounds and compositions for the treatment and/or prevention of various viral...  
WO/2024/076915A1
Compounds, compositions, and methods useful for treating a viral infection, such as human immunodeficiency virus (HIV) infection, are disclosed. In particular, 4'-thionucleoside analogues and methods for their preparation and use as ther...  
WO/2024/064701A2
The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.  
WO/2024/062413A1
The present disclosure includes oligonucleotides and nucleic acid compositions having stabilized phosphate moieties. Formula (Ia) and Formula (Ib), wherein: X is selected from a 3- to 5-membered cycloalkyl, -CHCH-, a 3- to 5-membered het...  
WO/2024/059609A1
The present disclosure relates to pharmaceutical forms of a CD73 inhibitor, polymorphic forms of the pharmaceutical forms, pharmaceutical compositions comprising the pharmaceutical forms, and methods of treating subjects having cancer by...  
WO/2024/059703A1
Provided herein are engineered terminal deoxynucleotidyl transferase (TdT) proteins with certain modifications, including mutations to confer thermal stability and to install an exposed amino acid residue to which a small molecule can be...  
WO/2024/055758A1
The present invention relates to the technical field of biological medicines. Disclosed are a cyclic dinucleotide metal compound, and a preparation method therefor and a use thereof. The structural formula of the compound is [M(cyclic di...  
WO/2024/059258A1
Click-labeled uridine bases, nucleosides, and phosphoramidites are provided, including improved methods of synthesis, oligonucleotides comprising the click-labeled nucleosides, methods of synthesizing spin-labeled oligonucleotides using ...  
WO/2024/054997A1
Provided herein are methods to treat rhegmatogenous retinal detachment (RRD) and/or improve visual outcomes of RRD.  
WO/2024/051696A1
The present invention relates to a compound for RNA capping and use thereof and belongs to the technical field of genetic engineering. The compound has a structure represented by formula I. The compound is used for capping an mRNA5' end,...  
WO/2024/050267A1
The present disclosure is directed to oligonucleotide dendrons comprising an oligonucleotide stem linked to one or more oligonucleotide branches. The disclosure also provides methods of using the oligonucleotide dendrons.  
WO/2024/049312A2
The first object of the invention is a method for the synthesis and purification of a nucleotide and/or a nucleoside. The second object of the invention is a modified nucleoside and/or a nucleotide, being a mono-, di- or triphosphate, co...  
WO/2023/007019A9
The present invention is inter alia concerned with (A) a compound of formula (I) as defined herein or a salt, stereoisomer, tautomer or deuterated version thereof, (B) a cap analog comprising a 5' terminal acyclonucleoside, wherein the a...  
WO/2024/040768A1
Disclosed in the present invention are a 5-pyridine-1H-indazole compound, a pharmaceutical composition, and a use. The structure of the compound is represented by formula I or II, and also comprised are an isomer or pharmaceutically acce...  
WO/2024/032718A1
The present invention relates to a crystal form of a hepatitis C inhibitor and the use thereof in a drug, and specifically relates to a crystal form A of a compound as represented by formula (I), a pharmaceutical composition of the cryst...  
WO/2024/034644A1
The present invention provides a compound for treating or preventing reduced intracellular ATP levels. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and...  
WO/2024/028729A1
The present disclosure relates to processes for the fluorination of molecules. One aspect provides a process for incorporating a fluorine atom into a molecule, said process comprising converting a compound of formula X—SG into a compou...  
WO/2024/029877A1
The present invention provides novel purine derivative compounds as A3 adenosine receptor agonists, hydrates thereof, solvates thereof, or pharmaceutically acceptable salts thereof. The novel purine derivatives of the present invention h...  
WO/2024/024766A1
The purpose of the present invention is to provide an alkylating agent that can alkylate a hydroxyl group at 2' position of a synthetic intermediate for an amidite compound in the presence of a base. The present invention provides an alk...  
WO/2024/017375A1
A cyclic substituted compound for RNA capping and use thereof, belonging to the technical field of genetic engineering. The compound has a structure represented by formula (VI). The compound is used for capping an mRNA 5' end, such that ...  
WO/2024/016639A1
Provided are a preparation of an anti-viral-infection compound, a method, a compound of formula (I), and a method and intermediate for synthesizing the compound of formula (I). The compound can inhibit the replication of SARS-CoV-2 and c...  
WO/2024/019137A1
The present invention relates to a production method of an oligonucleotide that includes a step for condensing, in the presence of an activator, a compound represented by formula (2) [wherein: G2 represents a protecting group of the hydr...  
WO/2024/014770A1
The present application relates to a modified RNA for preparing a mRNA vaccine and therapeutic agent, the modified RNA, according to one aspect, comprising a specific chemical modification and genetic modification and thus being capable ...  
WO/2024/012126A1
Disclosed in the present invention is a cordycepin-derivatized compound with an anti-tumor effect, which has a structure as represented by formula I. The cordycepin derivative and a pharmaceutical composition thereof provided in the pres...  
WO/2024/013349A1
The inventors have now succeeded in developing compounds of Formula (I), described below, having the advantage of inhibiting NAD kinases, in particular P. aeruginosa NADK (PaNADK) enzyme, Listeria monocytogenes (LmNADK) enzyme and/or hum...  
WO/2024/007068A1
A process for extracting TTX from biological material containing TTX, wherein the process comprises steps of extracting with a first solvent, concentrating, washing with a second solvent, concentrating again and purifying by chromatography.  
WO/2024/010810A2
The disclosure provides conjugates including an Fc domain monomer or Fc domain covalently linked to a moiety that binds to or inhibits CD73. The disclosure also provides pharmaceutical compositions including such conjugates and uses of s...  
WO/2024/002112A1
The present invention relates to use of a compound represented by formula (I) in resisting feline coronavirus or calicivirus infection. The compound represented by formula (I) efficiently inhibits the replication of feline coronavirus or...  
WO/2024/002045A1
Provided is an oligonucleotide delivery agent comprising at least one lipid moiety comprising at least one linear alkyl group or linear alkylenyl group directly or indirectly conjugated to a single-stranded oligonucleotide, which can be ...  
WO/2024/006376A1
The disclosure provides solid forms, e.g. salts and polymorphs, of the compound of Formula (I) and uses thereof. Also provided are the methods of making the solid forms and pharmaceutical formulations comprising the solid forms.  
WO/2024/006461A1
The present disclosure relates to solid forms (e.g. crystalline forms, solvates, and crystalline forms thereof) of a compound which is ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)- 5-cyano-3,4-dihydroxytetrahydrofuran-2-yl...  
WO/2024/002007A1
The present invention provides a double-stranded RNA comprising a nucleotide analog. The double-stranded RNA of the present invention exhibits one or more of enhanced stability, reduced off-target toxicity, and enhanced effectiveness.  
WO/2024/006953A2
The present disclosure relates to monomers and methods for synthesisizing modified oligonucleotides.  
WO/2023/249888A1
A composition that includes a micro-RNA mimic containing one or more cytosine nucleosides in which at least one cytosine nucleoside is replaced by cytosine arabinoside. Also provided is a method for killing a cancer cell by contacting it...  
WO/2023/250015A1
The present disclosure provides pyrimidine nucleoside compounds, including torcitabine, thymidine, deoxyuridine, deoxycytidine and uridine, and methods to treat telomere biology disorders (TBDs) and aging-related diseases, including hema...  
WO/2023/246860A1
The present invention provides an initially capped oligonucleotide primer, a method for preparing same, and use thereof, and particularly, provides an initially capped oligonucleotide primer comprising a hexose ring, a morpholine ring or...  
WO/2023/245040A1
Compounds, methods, and compositions for treating or preventing viral infections using flexible nucleosides analogs. The fleximer and reverse fleximer nucleoside analogues having increased flexibility and ability to alter their conformat...  
WO/2023/241699A1
The present disclosure relates to a cyclopentyl adenosine derivative and a pharmaceutical use thereof. Specifically, the present disclosure provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, whe...  
WO/2023/245037A1
The disclosure provides processes for preparing the compound of formula (VIa-1) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIa-1) are also provided.  
WO/2023/241587A1
The present invention provides an oligonucleotide having a cyclic phosphonate modification. The oligonucleotide of the present invention exhibits one or more among enhanced stability, reduced off-target toxicity, and enhanced effectiveness.  
WO/2023/239190A1
The present invention relates to a method for preparing 4'-thio-5-aza-2'-deoxycytidine which exhibits DNMT1 inhibitory activity. The production method according to the present invention can enhance reaction efficiency through efficient p...  
WO/2023/235362A1
Provided herein are compounds that are cap analogs for polynucleotides, e.g., RNA molecules, such as mRNA molecules. Also provided are capped polynucleotides, e.g., capped RNA molecules, such as capped mRNA molecules, wherein the 5' end ...  
WO/2023/233410A1
The present invention relates to crystalline polymorph Form I of benzyl N2- ((benzyloxy)carbonyl)-N4-(l-((2R,3S,4S,5R)-3,4-dihydroxy-5-( hydroxymethyl)tetrahydrofuran- 2-yl)-2-oxo-l,2-dihydropyrimidin-4-yl)-L-asparaginate (Compound 1), p...  
WO/2023/229884A2
3'-blocked nucleotides, methods of deblocking the same, and methods of synthesizing polynucleotides using the same are provided herein. In some examples, a nucleotide is disposed within the aperture on the first side of a nanopore. The n...  
WO/2023/228177A1
The present invention relates to novel compositions comprising (l-((2R,3S,4S,5R)-3,4- dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-l,2-d ihydropyrimidin-4-yl)-L-asparagine (also known as BST-236, Astarabine® or Aspacytarabine)...  
WO/2023/230061A2
Disclosed herein are compounds of formula or pharmaceutically acceptable salts thereof, and methods of using the same for treating a viral infection or inhibiting replication of a virus.  
WO/2023/224108A1
Provided is a nucleoside represented by formula (1). [In formula (1): R1 represents a hydroxyl group, a hydroxyl group in which the hydrogen atom is substituted by an alkyl or alkenyl group, or a protected hydroxyl group; R2 represents a...  
WO/2023/225042A1
Compounds, methods, and compositions for treating or preventing viral infections using flexible nucleosides analogs. The fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to pro...  
WO/2023/219427A1
The present invention relates to a pyrrolopyrimidinone carboxamide compound represented by chemical formula 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for treating cancer, co...  
WO/2023/217094A1
Disclosed in the present invention are a preparation method and the use of 2'-deoxyguanosine, guanosine and a composition of 2'-deoxyguanosine and guanosine. The present invention belongs to the technical field of the prevention and cont...  

Matches 1 - 50 out of 9,648